Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Varenicline adjunctive treatment in schizophrenia.

Trial Profile

Varenicline adjunctive treatment in schizophrenia.

Phase of Trial: Phase IV

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Varenicline (Primary)
  • Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 19 Mar 2012 Planned end date changed from 1 Jan 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 17 Aug 2011 Status changed from active, no longer recruiting to completed.
    • 07 Sep 2010 Planned end date changed from 1 Jun 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top